Gilead Sciences: Pharmaceutical Prices, Patents, And The FDA by Timothy D. Terrell, Mises Institute In this article by economist Jeffrey Sachs, pharmaceutical company Gilead is taken to task for selling its hepatitis C cure, Sofosbuvir (sold as Sovaldi), at a price of $84,000 per course of treatment. Sachs says that the actual production cost of Sofosbuvir is about $100. Sachs says that Gilead is “bilking the taxpayer” by charging the government prices far above production costs — and government is probably paying for most of the Sofosbuvir drugs. Sachs further complains that people will die because of Gilead’s refusal to…
Gilead Sciences: Pharmaceutical Prices, Patents, And The FDA
Guest Post
If you are interested in contributing to ValueWalk on a regular or one time basis read this post http://www.valuewalk.com/guest-posts-hedge-fund-letters/ We do not accept any outside posts or even ads on penny stocks, ICOs, cryptos, forex, binary options and related products.